Repurposing drugs to treat cardiovascular disease in the era of precision medicine
(2022) In Nature Reviews Cardiology 19(11). p.751-764- Abstract
Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that... (More)
Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities.
(Less)
- author
- Abdelsayed, Mena ; Kort, Eric J. ; Jovinge, Stefan LU and Mercola, Mark
- organization
- publishing date
- 2022-11
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nature Reviews Cardiology
- volume
- 19
- issue
- 11
- pages
- 14 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:35606425
- scopus:85130704629
- ISSN
- 1759-5002
- DOI
- 10.1038/s41569-022-00717-6
- language
- English
- LU publication?
- yes
- id
- 25ca4f9f-4b3d-4a3a-99db-5ffcb985b730
- date added to LUP
- 2022-12-30 08:50:59
- date last changed
- 2024-04-14 23:31:36
@article{25ca4f9f-4b3d-4a3a-99db-5ffcb985b730,
abstract = {{<p>Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities.</p>}},
author = {{Abdelsayed, Mena and Kort, Eric J. and Jovinge, Stefan and Mercola, Mark}},
issn = {{1759-5002}},
language = {{eng}},
number = {{11}},
pages = {{751--764}},
publisher = {{Nature Publishing Group}},
series = {{Nature Reviews Cardiology}},
title = {{Repurposing drugs to treat cardiovascular disease in the era of precision medicine}},
url = {{http://dx.doi.org/10.1038/s41569-022-00717-6}},
doi = {{10.1038/s41569-022-00717-6}},
volume = {{19}},
year = {{2022}},
}